Search

Your search keyword '"Kurtz, Christopher A."' showing total 214 results
Start Over Author "Kurtz, Christopher A."
214 results on '"Kurtz, Christopher A."'

3. Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab.

Author

Zimerman, André, O'Donoghue, Michelle L., Ran, Xinhui, KyungAh Im, Ott, Brian R., Mach, François, Zavitz, Kenton, Kurtz, Christopher E., Monsalvo, Maria Laura, Bei Wang, Atar, Dan, Keech, Anthony, Sabatine, Marc S., and Giugliano, Robert P.

Subjects
THERAPEUTIC use of monoclonal antibodies, PATIENT safety, COGNITIVE testing, EXECUTIVE function, STATISTICAL sampling, LDL cholesterol, ATHEROSCLEROSIS, DESCRIPTIVE statistics, RANDOMIZED controlled trials, LONGITUDINAL method, DRUG efficacy, SHORT-term memory, COGNITION, EVALUATION
Abstract

Background: Concerns persist regarding the cognitive safety of achieving very low levels of low-density lipoprotein (LDL) cholesterol. Although short-term studies are reassuring, the long-term cognitive effects of sustained exposure to very low LDL cholesterol levels through combined proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibition and statin therapy remain unknown. Methods: This prospective study enrolled a subset of adults with atherosclerotic cardiovascular disease who had completed a neurocognitive substudy (EBBINGHAUS) of a placebo-controlled randomized trial of evolocumab (FOURIER) and were eligible for a long-term open-label extension. The objective of this current study was to assess the long-term effect of evolocumab on cognitive function. Cognitive function was assessed annually, and the primary end point was change from baseline in executive function within each group, measured using the spatial working memory strategy index score (range, 4-28), with lower scores indicating better performance. Results: A total of 473 patients out of the 1974 patients in the parent EBBINGHAUS study were enrolled and additionally followed for a median of 5.1 years (maximum follow-up since original random assignment 7.2 years). The median age was 62 years; 70% were male, and 91% were White. At 12 weeks into the open-label extension period, median LDL cholesterol across the overall population was 35 mg/dl (interquartile range, 21-55 mg/dl). Treatment with evolocumab was not associated with a change in executive function during the open-label extension in either patients who were originally randomly assigned to and continued evolocumab (mean±standard deviation of 0.1±2.8, P=0.49) or patients originally randomly assigned to placebo who then started on evolocumab (-0.1±2.5, P=0.64). At the final study visit, executive function scores were similar between randomly assigned groups (17.5±3.7 and 17.3±3.7, respectively). Conclusions: Exposure to very low levels of LDL cholesterol, achieved via PCSK9 inhibition and statin therapy, was not associated with cognitive impairment through long-term follow-up. Further studies are needed to assess the generalizability to adults at higher risk of dementia. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

7. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Author

Raal, Frederick J, Hovingh, G Kees, Blom, Dirk, Santos, Raul D, Harada-Shiba, Mariko, Bruckert, Eric, Couture, Patrick, Soran, Handrean, Watts, Gerald F, Kurtz, Christopher, Honarpour, Narimon, Tang, Lihua, Kasichayanula, Sree, Wasserman, Scott M, and Stein, Evan A

Published
2017
Full Text
View/download PDF

12. Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial

Author

Murphy, Sabina A, Pedersen, Terje R, Gaciong, Zbigniew A, Ceska, Richard, Ezhov, Marat V, Connolly, Derek, Kraydashenko, Oleg, Jukema, J. Wouter, Toth, Kalman, Tikkanen, Matti J, Im, Kyungah, Wiviott, Stephen D, Kurtz, Christopher, Honarpour, Narimon, Giugliano, Robert P, Keech, Anthony C, Sever, Peter S, and Sabatine, Marc S

Published
2017

15. A Commentary

Author

Naval Postgraduate School (U.S.), Gillingham, Bruce, Kurtz, Christopher, Daniels, Daryl, Marler, Kenneth, Robertson, Amal, Naval Postgraduate School (U.S.), Gillingham, Bruce, Kurtz, Christopher, Daniels, Daryl, Marler, Kenneth, and Robertson, Amal

Abstract

It is with great interest that we read the article on the twentyfirst-century hospital ship by the esteemed Rear Adm. (ret.) Michael Baker, Mr. Jacob Baker, and Capt. (ret.) Fred “Skip” Burkle. Many of the concepts they outline are viable options worth consideration, but the future hospital ship is only one piece of the system-based, integrated approach for projecting medical power in support of Naval superiority.

Published
2022

16. No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab

Author

Korthauer, Laura E., primary, Giugliano, Robert P., additional, Guo, Jianping, additional, Sabatine, Marc S., additional, Sever, Peter, additional, Keech, Anthony, additional, Atar, Dan, additional, Kurtz, Christopher, additional, Ruff, Christian T., additional, Mach, Francois, additional, and Ott, Brian R., additional

Published
2022
Full Text
View/download PDF

17. A Commentary

Author

Gillingham, Bruce, primary, Kurtz, Christopher, additional, Daniels, Daryl, additional, Marler, Kenneth, additional, and Robertson, Amal, additional

Published
2022
Full Text
View/download PDF

18. A Commentary

Author

Gillingham, Bruce, Kurtz, Christopher, Daniels, Daryl, Marler, Kenneth, Robertson, Amal, and Naval Postgraduate School (U.S.)

Abstract

17 USC 105 interim-entered record; under review. It is with great interest that we read the article on the twentyfirst-century hospital ship by the esteemed Rear Adm. (ret.) Michael Baker, Mr. Jacob Baker, and Capt. (ret.) Fred “Skip” Burkle. Many of the concepts they outline are viable options worth consideration, but the future hospital ship is only one piece of the system-based, integrated approach for projecting medical power in support of Naval superiority. Identified in text as U.S. Government work.

Published
2022

21. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Author

Teerlink, John R., Diaz, Rafael, Felker, G. Michael, McMurray, John J.V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias‐Mendoza, Alexandra, Biering‐Sørensen, Tor, Böhm, Michael, Bonderman, Diana, Cleland, John G.F., Corbalan, Ramon, Crespo‐Leiro, Maria G., Dahlström, Ulf, Echeverria Correa, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Cândida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Lund, Mayanna, Macdonald, Peter, Mareev, Vyacheslav, Momomura, Shin‐ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J. A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Abbasi, Siddique A., Varin, Claire, Malik, Fady I., Kurtz, Christopher E., Besada, Diego Alejandro, Majul, Claudio Rodolfo, Bruno, Marco Raul Litvak, Sassone, Sonia, Avaca, Horacio Alberto, Rasmussen, Mariela, Aiub, Jorge Roberto, Hominal, Miguel Angel, Perna, Eduardo, Duran, Ruben Omar Garcia, Schiavi, Lilia, Marquez, Lilia Luz Lobo, Vilamajo, Oscar Alberto Gomez, Mackinnon, Ignacio, Fuente, Ricardo Alfonso Leon, Montana, Oscar Romano, Novaretto, Leonardo, Guerrero, Rodolfo Andres Ahuad, Brasca, Daniela Garcia, Prado, Aldo, Garrido, Marcelo Alejandro, Luquez, Hugo, Martinez, Diego Felipe, Nicolosi, Liliana, Parody, Maria Leonor, Zaidman, Cesar, Berra, Fernando Colombo, Ibañez, Julio, Zapata, Gerardo, Caccavo, Alberto, Colque, Roberto, Diez, Mirta, Poy, Carlos, Salomone, Oscar Alejandro, Vogel, Daniel, Bordonava, Anselmo Paulino, Fernandez, Alberto, French, John, Atherton, John, Hamilton, Andrew, Begg, Alistair, Abhayaratna, Walter, Judkins, Christopher, De Pasquale, Carmine, McKenzie, Scott, Amerena, John, Szto, Gregory, Kearney, Leighton, Zimmet, Hendrik, Sverdlov, Aaron, Beltrame, John, Korczyk, Dariusz, Sindone, Andrew, Moertl, Deddo, Huber, Kurt, Huelsmann, Martin, Ablasser, Klemens, Ebner, Christian, Siostrzonek, Peter, Drexel, Heinz, Poelzl, Gerhard, Dujardin, Karl, Dupont, Matthias, Buysschaert, Ian, Lancellotti, Patrizio, Droogne, Walter, Chouchane, Iman, Silveira, Fabio, Rassi, Salvador, Reis, Gilmar, Filho, Pedro Pimentel, Simoes, Marcus Vinicius, Braga, Joao Carlos, Giorgeto, Flavio Eduardo, Ferraz, Almir, Jaeger, Cristiano Pederneiras, Saraiva, Jose Francisco, Tognon, Alexandre, Cardoso, Juliano, Greco, Oswaldo, Paiva, Maria Sanali, Paolino, Bruno, Filho, Otavio Coelho, Maia, Lilia Nigro, Silva, Rodrigo, Canesin, Manoel, Rossi, Paulo Roberto Ferreira, Fortes, Jose Augusto Ribas, Cerci, Rodrigo Julio, Manenti, Euler Roberto Fernandes, Leaes, Paulo Ernesto, Silva Neto, Luis Beck, Souza, Weimar Kunz Barroso, Bacal, Fernando, Chaves, Renato, Ramires, Felix, Vidotti, Maria Helena, Barros e Silva, Pedro Gabriel Melo, Piegas, Leopoldo Soares, Todorov, Georgi, Tzekova, Maria, Goudev, Assen, Mincheva, Valentina, Vasilev, Ivaylo, Tisheva‐ Gospodinova, Snezhanka, Petrov, Ivo, Postadzhiyan, Arman, Velikov, Chavdar, Dimov, Bojidar, Constance, Christian, Phaneuf, Denis‐Carl, Mielniczuk, Lisa, Pandey, A Shekhar, Senaratne, Manohara, Zieroth, Shelley, Savard, Daniel, Stewart, Robert, Huynh, Thao, Giannetti, Nadia, Moe, Gordon, Bourgeois, Ronald, Ezekowitz, Justin, Hartleib, Michael, Sussex, Bruce, Babapulle, Mohan, Chehayeb, Raja, Gaudet, Daniel, McKelvie, Robert, Nguyen, Viviane, Roth, Sherryn, Gupta, Milan, Pesant, Yves, Rupka, Dennis, Bhargava, Rakesh, Costa‐Vitali, Atilio, Proulx, Guy, Vega, Mario, Potthoff, Sergio, Cid, Maria Cristina Schnettler, Sepulveda, Alex Mauricio Villablanca, Zanetti, Fernando Tomas Lanas, Gajardo, Victor Areli Saavedra, Kindel, Carlos Conejeros, Jofre, Christian Paolo Pincetti, Segarra, Jorge Leonardo Cobos, Venegas, Manuel Eduardo Rodriguez, Hidalgo, Mario Yanez, Jalaf, Margarita Gertrudis Vejar, Li, Weimin, Zhang, Jinguo, Fu, Xin, Zhang, Xuelian, Li, Dongye, Wang, Zhifang, Qu, Yanling, Zheng, Zhe, Tang, Huifang, Yang, Ping, Zhang, Yuhui, Zheng, Yang, Mi, Yafei, Huang, He, Bu, Peili, Chen, Guoqin, Chen, Jiyan, Han, Yajun, Li, Zhangquan, Ma, Shumei, Yang, Xuming, Yuan, Zuyi, Dong, Yugang, Li, Zhaoping, Mahemuti, Ailiman, Niu, Wentang, Yang, Zhenyu, Zhang, Yuqing, Sun, Yuemin, Wu, Weiheng, Liu, Feng, Yan, Jing, Li, Yinjun, Wang, Yi, Zhang, Shouyan, Zhou, Changyong, Cui, Hanbin, Li, Jianjun, Li, Tianfa, Han, Qinghua, Wei, Yu, Correa, Luis Eduardo Echeverria, Mendoza, Jose Luis Accini, Jattin, Fernando Manzur, Osorio, Wilder Castaño, Luengas, Carlos Alberto, Arroyo, Julian Alonso Coronel, Corredor, Miguel Alfredo Moncada, Giraldo, Clara Ines Saldarriaga, Lopez, Rodrigo Botero, Salazar, Dora Ines Molina, Triana, Miguel Urina, Lopez, Luis Horacio Atehortua, Rojas, Pastor Olaya, Pelaez, Sebastian Velez, Pareja, Monica Lopez, Bonfanti, Alberto Cadena, Polasek, Rostislav, Monhart, Zdenek, Sochor, Karel, Motovska, Zuzana, Belohlavek, Jan, Busak, Ladislav, Krupicka, Jiri, Tyl, Petr, Jerabek, Ondrej, Podpera, Ivo, Skrobakova, Janka, Peterka, Karel, Spacek, Rudolf, Cech, Vladimir, Kellnerova, Ivana, Nechvatal, Libor, Pozdisek, Zbynek, Houra, Marek, Kryza, Radim, Machova, Vilma, Cepelak, Michal, Stepek, David, Zeman, Kamil, Klimsa, Zdenek, Koleckar, Pavel, Schee, Alexandr, Spinarova, Lenka, Coufal, Zdenek, Jeppesen, Jorgen, Vraa, Soren, Wiggers, Henrik, Nyvad, Ole, Nielsen, Tonny, Kaiser‐Nielsen, Peter, Videbaek, Lars, Galinier, Michel, Lefebvre, Jean‐Marie, Tartiere, Jean‐Michel, De Geeter, Guillaume, Roubille, Francois, Ricci, Jean Etienne, Salvat, Muriel, Gueffet, Jean‐Pierre, Decoulx, Eric, Berdague, Philippe, Jondeau, Guillaume, Ovize, Michel, Groote, Pascal De, Donal, Erwan, Isnard, Richard, Sabatier, Rémi, Trochu, Jean Noel, Damy, Thibaud, Georges, Jean‐Louis, Rosamel, Yann, Picard, François, Aboyans, Victor, Laperche, Thierry, Mitrovic, Veselin, Taggeselle, Jens, Störk, Stefan, Ebelt, Henning, Genth‐Zotz, Sabine, Rassaf, Tienush, Duengen, Hans‐Dirk, Mittag, Marcus, Menck, Niels, Zeymer, Uwe, Haehling, Stephan, Boehm, Michael, Frankenstein, Lutz, Killat, Holger, Bourhaial, Hakima, Beug, Daniel, Horacek, Thomas, Pfister, Roman, Sandri, Marcus, Westenfeld, Ralf, Kadel, Christoph, Karvounis, Haralambos, Patsilinakos, Sotirios, Mantas, Ioannis, Karavidas, Apostolos, Giamouzis, Grigorios, Tsioufis, Konstantinos, Naka, Katerina, Tziakas, Dimitrios, Parissis, John, Styliadis, Ioannis, Barbetseas, Ioannis, Manolis, Athanasios, Kochiadakis, George, Herczeg, Bela, Nagy, Laszlo, Nyolczas, Noemi, Toth, Kalman, Merkely, Bela, Laszlo, Zoltan, Mark, Laszlo, Szakal, Imre, Papp, Andras, Bezzegh, Katalin, Lakatos, Ferenc, Hajko, Erik, Papp, Aniko, Forster, Tamas, Lupkovics, Geza, Mohacsi, Attila, Salamon, Csaba, Aradi, Daniel, Andreka, Peter, Szasz, Gyula, Zilahi, Zsolt, Kazinczy, Rita, Margonato, Alberto, Agostoni, Piergiuseppe, Fucili, Alessandro, Piovaccari, Giancarlo, Senni, Michele, Carluccio, Erberto, Bilato, Claudio, Frigerio, Maria, Indolfi, Ciro, Sinagra, Gianfranco, Brunetti, Natale Daniele, Perna, Gianpiero, Pini, Daniela, Volterrani, Maurizio, Leonardi, Sergio, Mortara, Andrea, Friz, Hernan Emilio Francisco Polo, Rossini, Roberta, Tocchetti, Carlo Gabriele, Vincenzi, Antonella, Cavallini, Claudio, Floresta, Agata Marina, Zaca, Valerio, Giudici, Vittorio, Villani, Giovanni Quinto, Higashino, Yorihiko, Oishi, Shogo, Wada, Atsuyuki, Fukuzawa, Shigeru, Onoue, Kenji, Koike, Akihiro, Koizumi, Tomomi, Masuda, Seigo, Mitsuo, Kazuhisa, Takahashi, Natsuki, Takenaka, Takashi, Tanabe, Jun, Watanabe, Naoki, Yoshida, Takeshi, Amano, Tetsuya, Ishikawa, Masahiro, Kida, Keisuke, Kubota, Toru, Nakamura, Kentaro, Sakamoto, Tomohiro, Shimomura, Mitsuhiro, Yuge, Masaru, Doi, Masayuki, Domae, Hiroshi, Ebato, Mio, Fujii, Kenshi, Fujiwara, Wakaya, Gohara, Seiichiro, Hata, Yoshiki, Kanda, Junji, Kitaoka, Hiroaki, Matsumoto, Takashi, Michishita, Ichiro, Miura, Shinichiro, Miyazaki, Tetsuro, Nakamura, Akihiro, Ogawa, Tomohiro, Okumura, Takahiro, Okumura, Yasuo, Sakai, Tetsuo, Sato, Yukihito, Shimizu, Wataru, Sugino, Hiroshi, Suzuki, Masahiro, Takagi, Atsutoshi, Takaishi, Hiroshi, Tanaka, Takahiro, Terasaki, Toshiro, Tsujimoto, Mitsuru, Ueda, Yasunori, Ujino, Keiji, Usui, Makoto, Yamamoto, Mitsutaka, Yoshikawa, Masaki, Ando, Kenji, Asakura, Masanori, Asano, Hiroshi, Fujii, Shigeru, Hara, Hisao, Inomata, Takayuki, Isshiki, Takaaki, Kadokami, Toshiaki, Kai, Hisashi, Kasai, Toshio, Kawamitsu, Katsunori, Kawasaki, Tomohiro, Koga, Tokushi, Komiyama, Nobuyuki, Maejima, Yasuhiro, Manita, Mamoru, Miyamoto, Nobuhide, Node, Koichi, Numaguchi, Kotaro, Sakata, Yasushi, Serikawa, Takeshi, Takama, Noriaki, Tatebe, Shunsuke, Ueno, Hideki, Hidaka, Takayuki, Hiroi, Shitoshi, Iseki, Harukazu, Ito, Hiroshi, Kajinami, Kouji, Kawakami, Hideo, Momiyama, Yukihiko, Mori, Masuki, Morita, Yukiko, Okishige, Kaoru, Sakagami, Satoru, Takeishi, Yasuchika, Terasawa, Akihiro, Utsu, Noriaki, Badariene, Jolita, Celutkiene, Jelena, Slapikas, Rimvydas, Jarasuniene, Dalia, Castillo, Armando Garcia, De los Rios Ibarra, Manuel Odin, Lopez, Gabriel Arturo Ramos, Llamas, Edmundo Alfredo Bayram, Esperon, Guillermo Antonio Llamas, Vazquez, Eduardo Salcido, Gonzalez, Ricardo Garcia, Leon, Jose Luis Arenas, Gonzalez, Salvador Leon, Mendoza, Maria Alexandra Arias, Rodriguez, Alicia Contreras, Machado, Gustavo Francisco Mendez, Salazar, Melchor Alpizar, Ruiz, Alberto Esteban Bazzoni, Flores, Ana Maria De Leon, Carrasco, Jose Alfredo Pagola, Araiza, Raul Reyes, Römer, Tjeerd, Remmen, Johannes, Van Eck, Jacob, Elvan, Arif, Smilde, Tom, Voors, Adriaan, Wal, Ruud, Schaap, Jeroen, Sluis, Aize, Linssen, Gerardus, Magro, Michael, Willems, Frank, Hal, John, Zwaan, Coenraad, Beelen, Driek, Boswijk, Dirk, Hermans, Walter, Van Kesteren, Henricus, Scott, Russell, Hart, Hamish, Lund, Marianne, Szczasny, Marcin, Blicharski, Tomasz, Kafara, Mariusz, Stankiewicz, Anna, Skonieczny, Grzegorz, Zabowka, Maciej, Kania, Grzegorz, Kopaczewski, Jerzy, Pawlowicz, Lidia, Spyra, Janusz, Wlodarczyk, Aleksander, Sciborski, Ryszard, Balsam, Pawel, Drozdz, Jaroslaw, Sobkowicz, Bozena, Konieczynska, Malgorzata, Lelonek, Malgorzata, Bednarkiewicz, Zbigniew, Trebacz, Jaroslaw, Jankowski, Piotr, Sidor, Mateusz, Berkowski, Piotr, Chmielak, Zbigniew, Lenartowska, Lucyna, Nessler, Jadwiga, Straburzynska‐Migaj, Ewa, Kalarus, Zbigniew, Kowalski, Robert, Kalecinska‐Krystkiewicz, Ewa, Gola, Zbigniew, Pijanowski, Zbigniew, Wozakowska‐Kaplon, Beata, Cymerman, Krzysztof, Rynkiewicz, Andrzej, Miekus, Pawel, Monteiro, Pedro, Sarmento, Pedro Morais, Almeida, Filipa, Duarte, Tatiana, Fonseca, Candida, Oliveira, Luis, Santos, Luis, Brito, Dulce, Stanciulescu, Gabriela, Spiridon, Marilena Renata, Militaru, Constantin, Podoleanu, Cristian Gheorghe, Zdrenghea, Dumitru, Popescu, Mircea Ioachim, Macarie, Cezar‐Eugen, Giuca, Alina, Mitu, Florin, Voicu, Olga‐Cristina, Dorobantu, Maria, Lighezan, Daniel, Stamate, Sorin, Bykov, Alexander, Kobalava, Zhanna, Zrazhevskiy, Konstantin, Semenova, Irina, Vishnevsky, Alexander, Shutemova, Elena, Tereschenko, Sergey, Shvarts, Yury, Barbarash, Olga, Lukyanov, Yury, Voevoda, Mikhail, Dovgolis, Svetlana, Dronov, Dmitry, Goloshchekin, Boris, Sitnikova, Maria, Ezhov, Marat, Tarasov, Nikolay, Kotelnikov, Mikhail, Kostenko, Viktor, Solovev, Oleg, Goncharov, Ivan, Myasnikov, Roman, Rafalskiy, Vladimir, Ryabov, Vyacheslav, Kosmacheva, Elena, Motylev, Igor, Nosov, Vladimir, Osipova, Irina, Salukhov, Vladimir, Belenkiy, Dmitriy, Bolshakova, Olga, Pimenov, Leonid, Shilkina, Nataliya, Kulibaba, Elena, Repin, Alexey, Timofeev, Alexander, Mitrokhin, Vladislav, Sherenkov, Alexander, Arbolishvili, Georgy, Antalik, Lubomir, Dzupina, Andrej, Fulop, Peter, Majercak, Ivan, Gonsorcik, Jozef, Vinanska, Daniela, Lenner, Egon, Lukacova, Jana, Margoczy, Roman, Smik, Rudolf, Stevlik, Jan, Uhliar, Rudolf, Burgess, Lesley, Badat, Aysha, Klug, Eric, Van Zyl, Louis, Abelson, Mark, Moodley, Rajendran, Tsabedze, Nqoba, Fourie, Nyda, Bonet, Luis Almenar, Prado, Jose Maria Arizon, Oliveira Soares, Manue Martinez‐Selles D, Villota, Julio Eduardo Nuñez, Leiro, Maria Generosa Crespo, Juanatey, Jose Ramon Gonzalez, Figal, Domingo Andres Pascual, Palomas, Juan Luis Bonilla, Perez, Sonia Mirabet, Jimenez, Juan Francisco Delgado, Padron, Antonio Lara, Diaz, Victor Alfonso Jimenez, Cubero, Javier Segovia, Paya, Vicente Eduardo Climent, Mayoral, Alejandro Recio, Fuente Galan, Luis, Doblas, Juan Jose Gomez, Freire, Ramon Bover, Peiro, Maria Teresa Blasco, Molina, Beatriz Diaz, Martinez, Laura Jordan, Vilchez, Francisco Gonzalez, Boman, Kurt, Karlstrom, Patric, Berglund, Stefan, Szabo, Barna, Peterson, Magnus, Wodlin, Peter, Lindholm, Carl‐Johan, Moccetti, Tiziano, Mueller, Christian, Suter, Thomas, Hullin, Roger, Meyer, Philippe, Noll, Georg, Yigit, Zerrin, Turgut, Okan Onur, Bekar, Lutfu, Sahin, Tayfun, Koldas, Zehra Lale, Celik, Ahmet, Cavusoglu, Yuksel, Demir, Mesut, Onrat, Ersel, Duzenli, Mehmet, Cosansu, Kahraman, Muderrisoglu, Ibrahim Haldun, Tuncer, Mustafa, Badak, Ozer, Nalbantgil, Sanem, Kirma, Cevat, Okuyan, Ertugrul, Guray, Umit, Prokhorov, Oleksandr, Karpenko, Oleksandr, Vakaliuk, Igor, Yagensky, Andriy, Kracz, Igor, Stanislavchuk, Mykola, Kulynych, Oleksii, Rishko, Mykola, Stets, Roman, Tseluyko, Vira, Mishchenko, Larysa, Rudenko, Leonid, Rudyk, Iurii, Alieksieieva, Liudmyla, Korzh, Oleksii, Mostovoy, Yuriy, Parkhomenko, Oleksandr, Rasputina, Lesya, Voronkov, Leonid, Lymar, Yurii, Vasilyeva, Larysa, Keeling, Philip, Barr, Craig, Wong, Kenneth, Price, Dallas, Skaria, Binoy, Clark, Andrew, Chandrasekaran, Badrinathan, Trevelyan, Jasper, Gordon, Brian, Donnelly, Patrick, Glover, Jason, Ryding, Alisdair, Weir, Robin, Lang, Chim, Roy, Debashis, Adhya, Shaumik, Clifford, Piers, Ludman, Andrew, Kalra, Paul, Lynch, Mary, Mahmood, Shahid, Al Mohammad, Abdallah, Asubiaro, Joshua, Elmahi, Einas, Muthumala, Amal, Taylor, Justin, Gupta, Dinesh, Nadar, Venkatesh, Henderson, David, Zolty, Ronald, Sauer, Andrew, Adams, Kirkwood, Chandra, Lokesh, Jaffrani, Naseem, Grewal, Gurinder, Mancini, Donna, McLean, Dalton, Vasallo, Javier, Gottlieb, Stephen, Joseph, Susan, Barua, Rajat, Gorodeski, Eiran, Mouhaffel, Asad, Chung, Eugene, Desai, Pratik, Portnay, Edward, Rama, Bhola, Shandling, Adrian, Stahl, Llyod, Heilman, Karl, Jacob, Binu, Londono, Juan, Almousalli, Omar, Ashcom, Thomas, Bauerlein, Eugene Joseph, Koo, Charles, McGrew, Frank, Rajagopalan, Navin, Robinson, Shawn, Schultz, David, Starling, Randall, Ambardekar, Amrut, Bhagwat, Ravi, Boehmer, John, Bouza, Manuel, Farris, Neil, Feitell, Scott, Ganji, Jagadeesh, Geltman, Edward, Javier, Julian, Morrow, John Andrew, Pianko, Leonard, Smart, Frank, Adler, Alexander, Brinkley, Douglas, Cardona, Jose, Coletti, Andrew, Harris, John, Hunter, Vernon, Krantz, Mori, Lang, Christopher, Lovell, Charles, Murray, David, Pillutla, Priya, Shah, Amit, Bogaev, Roberta, Dauber, Ira, Franchi, Francesco, Fremont, Richard, Hart, Terence, Hattler, Brack, Janik, Matthew, Khalife, Wissam, Malhotra, Sanjay, Mamdani, Shafiq, Nelson, William, Orgera, Marisa, Ortiz, Aurelio, Rahko, Peter, Rennyson, Stephen, Shin, Jooyoung, Tsao, Lana, Uretsky, Barry, Wahid, Faisal, Wilkett, Matt, Amanullah, Aman, Baker, Mathue, Berk, Martin, Boccalandro, Fernando, Cruz, Kimberly, Doyle, Timothy, Gianfagna, Robert, Jones, Alonzo, King, Anthony, Lepor, Norman, Martinez‐Castrillon, Melvin, Pham, Michael, Radin, Michael, Radojevic, Joseph, Ramanathan, Kodangudi, Schmalfuss, Carsten, Schnitzler, Robert, Shah, Keyur, Takata, Theodore, Bertolet, Barry, Bostick, Brian, Civitello, Andrew, Collins, John, Dib, Nabil, Fang, James, Gilmore, Richard, Gray, Wayne, Grazette, Luanda, Haddad, Tariq, Hearne, Steven, Janmohamed, Munir, Katz, Richard, Kazemi, Navid, Llerena, Sara, Lohr, Nicole, Marzouka, George, Mignone, John, Ooi, Henry, Paszczuk, Anna, Pickett, Christopher, Sampognaro, Gregory, Sawyer, Douglas, Shayani, Steven, Treasure, Charles, Vaz, Garth, Vijay, Nampalli, Williams, Celeste, Yeoman, Gary, Zhang, Lily, Aaronson, Keith, Abo‐Auda, Wael, Alharethi, Rami, Anderson, William, Ariani, Mehrdad, Banerji, Sourin, Baweja, Paramdeep, Carson, Peter, Eberly, Arthur, Elliott, James, Fernando, Ronald, Fisher, Daniel, Forman, Steven, Gabriel, George, Gogia, Harinder, Hametz, Craig, Houston, Brian, Ibrahim, Hassan, Jadbabaie, Farid, Kassiotis, Christos, Krishnamoorthy, Arun, Kwan, Michael, Lupovitch, Steven, Macias, Leonardo, Malik, Adnan, Martinez, Luis, Miyamoto, Michael, Mody, Freny, Patel, Devesh, Peart, Brenda, Pisani, Barbara, Ramos, Mark, Rivero, Mariel, Shah, Anil, Sharma, Mukesh, Sichrovsky, Tina, Simon, Marc, Singh, Deovrat, Tallet, Julio, Vaccari, Christopher, Villoch, Mario, Wheeler, Matthew, Yousuf, Kabir, Abadier, Rafik, Abdullah, Shuaib, Arora, Raveen, Aslam, Shamaila, Buynak, Robert, Chang, David, Contreras, Johanna, Halpern, Stephen, Handel, Franklin, Heitner, John, Herzog, William, Jackson, Bruce, Kao, John, Kondo, Nicholas, Koren, Michael, LeWinter, Martin, Martindale, Jeffrey, Martinez‐Arraras, Joaquin, Olsen, Stephanie, Piatek, Marek, Ranadive, Nandkishore, Randall, William, Rao, Sunder, Rawitscher, David, Rider, James, Sokos, George, Strader, J Russell, Sulemanjee, Nasir, Tahirkheli, Naeem, Trichon, Benjamin, Vanhecke, Thomas, Whellan, David, Abuannadi, Mohammad, Aggarwala, Gaurav, Ahmad, Saad, Artis, Andre, Cheirif, Jorge, Cotarlan, Vladimir, Cox, Jeremy, Eaton, Charles, Florea, Viorel, Frank, Theodore, Friedman, Keith, Ganeshram, Vedampattu, Gass, Alan, Gemignani, Anthony, Hasni, Syed, Hedgepeth, Chester, Itchhaporia, Dipti, Kaluski, Edo, Karim, Amin, Kono, Alan, Lader, Ellis, Lakshminarayanan, Batlagundu, Lewis, Neil, Malhotra, Vinay, Mayer, Nolan, Mohapatra, Robert, Nair, Nandini, O'Brien, Terrence, Pauwaa, Sunil, Rowan, Christopher, Saxena, Sanjeev, Seto, Arnold, Shah, Nishant, Singh, Pradeep, Skopicki, Hal, Stoddard, Marcus, and Sweitzer, Nancy

Subjects
R1
Abstract

Aims:\ud The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials.\ud \ud Methods and Results:\ud Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure

Published
2020

22. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)

Author

Biering-Sørensen, Tor, Minamisawa, Masatoshi, Liu, Jiankang, Claggett, Brian, Papolos, Alexander I., Felker, G. Michael, McMurray, John J.V., Legg, Jason C., Malik, Fady I., Honarpour, Narimon, Kurtz, Christopher E., Teerlink, John R., Solomon, Scott D., Biering-Sørensen, Tor, Minamisawa, Masatoshi, Liu, Jiankang, Claggett, Brian, Papolos, Alexander I., Felker, G. Michael, McMurray, John J.V., Legg, Jason C., Malik, Fady I., Honarpour, Narimon, Kurtz, Christopher E., Teerlink, John R., and Solomon, Scott D.

Published
2021

23. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Author

Teerlink, John R., Diaz, Rafael, Michael Felker, G., McMurray, John J.V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias-Mendoza, Alexandra, Biering-Sorensen, Tor, Bohm, Michael, Bonderman, Diana, Cleland, John G.F., Corbalan, Ramon, Crespo-Leiro, Maria G., Dahlstrom, Ulf, Echeverria, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Candida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Li, Jing, Lund, Mayanna, Macdonald, Peter, Mareev, Viacheslav, Momomura, Shin'ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J.A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Varin, Claire, Honarpour, Narimon, Abbasi, Siddique A., Malik, Fady I., Kurtz, Christopher E., Teerlink, John R., Diaz, Rafael, Michael Felker, G., McMurray, John J.V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias-Mendoza, Alexandra, Biering-Sorensen, Tor, Bohm, Michael, Bonderman, Diana, Cleland, John G.F., Corbalan, Ramon, Crespo-Leiro, Maria G., Dahlstrom, Ulf, Echeverria, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Candida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Li, Jing, Lund, Mayanna, Macdonald, Peter, Mareev, Viacheslav, Momomura, Shin'ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J.A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Varin, Claire, Honarpour, Narimon, Abbasi, Siddique A., Malik, Fady I., and Kurtz, Christopher E.

Abstract

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.).

Published
2021

24. [K.sub.ATP] channel knockout worsens myocardial calcium stress load in vivo and impairs recovery in stunned heart

Author

Gumina, Richard J., O'Cochlain, D. Fearghas, Kurtz, Christopher E., Bast, Peter, Pucar, Darko, Mishra, Prasanna, Miki, Takashi, Seino, Susumu, Macura, Slobodan, and Terzic, Andre

Subjects
Adenosine triphosphatase genes -- Research, Genetically modified mice -- Research, Magnetic resonance imaging -- Usage, Dobutamine -- Physiological aspects, Dobutamine -- Research, Biological sciences
Abstract

Gene knockout of the KCNJ11-encoded Kir6.2 ATP-sensitive [K.sup.+] ([K.sub.ATP]) channel implicates this stress-response element in the safeguard of cardiac homeostasis under imposed demand. [K.sub.ATP] channels are abundant in ventricular sarcolemma, where subunit expression appears to vary between the sexes. A limitation, however, in establishing the full significance of [K.sub.ATP] channels in the intact organism has been the inability to monitor in vivo the contribution of the channel to intracellular calcium handling and the superimposed effect of sex that ultimately defines heart function. Here, in vivo manganese-enhanced cardiac magnetic resonance imaging revealed, under dobutamine stress, a significantly greater accumulation of calcium in both male and female [K.sub.ATP] channel knockout (Kir6.2-KO) mice compared with sex- and age-matched wild-type (WT) counterparts, with greatest calcium load in Kir6.2-KO females. This translated, poststress, into a sustained contracture manifested by reduced end-diastolic volumes in [K.sub.ATP] channel-deficient mice. In response to ischemia-induced stunning, male and female Kir6.2-KO hearts demonstrated accelerated time to contracture and increased peak contracture compared with WT. The outcome on reperfusion, in both male and female Kir6.2-KO hearts, was a transient reduction in systolic performance, measured as rate-pressure product compared with WT, with protracted increase in left ventricular end-diastolic pressure, exaggerated in female knockout hearts, despite comparable leakage of creatine kinase across groups. Kir6.2-KO hearts were rescued from diastolic dysfunction by agents that target alternative pathways of calcium handling. Thus [K.sub.ATP] channel deficit confers a greater susceptibility to calcium overload in vivo, accentuated in female hearts, impairing contractile recovery under various conditions of high metabolic demand. ATP-sensitive [K.sup.+] channel; Kir6.2; magnetic resonance imaging; myocardium; sex

Published
2007

27. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure ( COSMIC ‐ HF )

Author

Biering‐Sørensen, Tor, primary, Minamisawa, Masatoshi, additional, Liu, Jiankang, additional, Claggett, Brian, additional, Papolos, Alexander I., additional, Felker, G. Michael, additional, McMurray, John J.V., additional, Legg, Jason C., additional, Malik, Fady I., additional, Honarpour, Narimon, additional, Kurtz, Christopher E., additional, Teerlink, John R., additional, and Solomon, Scott D., additional

Published
2021
Full Text
View/download PDF

28. Knockout of Kir6.2 negates ischemic preconditioning-induced protection of myocardial energetics

Author

Gumina, Richard J., Pucar, Darko, Bast, Peter, Hodgson, Denice M., Kurtz, Christopher E., Dzeja, Petras P., Miki, Takashi, Seino, Susumu, and Terzic, Andre

Subjects
Human physiology -- Research, Biological sciences
Abstract

Although ischemic preconditioning induces bioenergetic tolerance and thereby remodels energy metabolism that is crucial for postischemic recovery of the heart, the molecular components associated with preservation of cellular energy production, transfer, and utilization are not fully understood. Here myocardial bioenergetic dynamics were assessed by [sup.18]O-assisted [sup.31]P-NMR spectroscopy in control or preconditioned hearts from wild-type (WT) or Kir6.2-knockout (Kir6.2-KO) mice that lack metabolism-sensing sarcolemmal ATP-sensitive [K.sup.+] ([K.sub.ATP]) channels. In WT vs. Kir6.2-KO hearts, preconditioning induced a significantly higher total ATP turnover (232 [+ or -] 20 vs. 155 [+ or -] 15 nmol*mg [protein.sup.-1*[min.sup.-1]), ATP synthesis rate (58 [+ or -] 3 vs. 46 [+ or -] 3% [sup.18]O labeling of [gamma]-ATP), and ATP consumption rate (51 [+ or -] 4 vs. 31 [+ or -] 4% [sup.18]O labeling of [P.sub.i]) after ischemia-reperfusion. Moreover, preconditioning preserved cardiac creatine kinase-catalyzed phosphotransfer in WT (234 [+ or -] 26 nmol*mg [protein.sup-1]* [min.sup.-1]) but not Kir6.2-KO (133 [+ or -] 18 nmol*mg [protein.sup.-1]*[min.sup.-1]) hearts. In contrast with WT hearts, preconditioning failed to preserve contractile recovery in Kir6.2-KO hearts, as tight coupling between postischemic performance and high-energy phosphoryl transfer was compromised in the [K.sub.ATP]-channel-deficient myocardium. Thus intact [K.sub.ATP] channels are integral in ischemic preconditioning-induced protection of cellular energetic dynamics and associated cardiac performance. ATP-sensitive [K.sup.+] channel; cardioprotection; ischemia; metabolism

Published
2003

30. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Author

Teerlink, John R., primary, Diaz, Rafael, additional, Felker, G. Michael, additional, McMurray, John J.V., additional, Metra, Marco, additional, Solomon, Scott D., additional, Adams, Kirkwood F., additional, Anand, Inder, additional, Arias-Mendoza, Alexandra, additional, Biering-Sørensen, Tor, additional, Böhm, Michael, additional, Bonderman, Diana, additional, Cleland, John G.F., additional, Corbalan, Ramon, additional, Crespo-Leiro, Maria G., additional, Dahlström, Ulf, additional, Echeverria, Luis E., additional, Fang, James C., additional, Filippatos, Gerasimos, additional, Fonseca, Cândida, additional, Goncalvesova, Eva, additional, Goudev, Assen R., additional, Howlett, Jonathan G., additional, Lanfear, David E., additional, Li, Jing, additional, Lund, Mayanna, additional, Macdonald, Peter, additional, Mareev, Viacheslav, additional, Momomura, Shin-ichi, additional, O’Meara, Eileen, additional, Parkhomenko, Alexander, additional, Ponikowski, Piotr, additional, Ramires, Felix J.A., additional, Serpytis, Pranas, additional, Sliwa, Karen, additional, Spinar, Jindrich, additional, Suter, Thomas M., additional, Tomcsanyi, Janos, additional, Vandekerckhove, Hans, additional, Vinereanu, Dragos, additional, Voors, Adriaan A., additional, Yilmaz, Mehmet B., additional, Zannad, Faiez, additional, Sharpsten, Lucie, additional, Legg, Jason C., additional, Varin, Claire, additional, Honarpour, Narimon, additional, Abbasi, Siddique A., additional, Malik, Fady I., additional, and Kurtz, Christopher E., additional

Published
2021
Full Text
View/download PDF

32. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia

Author

Santos, Raul D., primary, Ruzza, Andrea, additional, Hovingh, G. Kees, additional, Wiegman, Albert, additional, Mach, François, additional, Kurtz, Christopher E., additional, Hamer, Andrew, additional, Bridges, Ian, additional, Bartuli, Andrea, additional, Bergeron, Jean, additional, Szamosi, Tamás, additional, Santra, Saikat, additional, Stefanutti, Claudia, additional, Descamps, Olivier S., additional, Greber-Platzer, Susanne, additional, Luirink, Ilse, additional, Kastelein, John J.P., additional, and Gaudet, Daniel, additional

Published
2020
Full Text
View/download PDF

33. The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (cosmic-hf)

Author

Biering-Sørensen, Tor, primary, Papolos, Alexander, additional, Teerlink, John R., additional, Felker, G. Michael, additional, McMurray, John J.V., additional, Legg, Jason C., additional, Malik, Fady I., additional, Honarpour, Narimon, additional, Kurtz, Christopher E., additional, and Solomon, Scott D., additional

Published
2020
Full Text
View/download PDF

35. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction

Author

Gencer, Baris, primary, Mach, François, additional, Murphy, Sabina A., additional, De Ferrari, Gaetano M., additional, Huber, Kurt, additional, Lewis, Basil S., additional, Ferreira, Jorge, additional, Kurtz, Christopher E., additional, Wang, Huei, additional, Honarpour, Narimon, additional, Keech, Anthony C., additional, Sever, Peter S., additional, Pedersen, Terje R., additional, Sabatine, Marc S., additional, and Giugliano, Robert P., additional

Published
2020
Full Text
View/download PDF

36. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction

Author

Wiviott, Stephen D., primary, Giugliano, Robert P., additional, Morrow, David A., additional, De Ferrari, Gaetano M., additional, Lewis, Basil S., additional, Huber, Kurt, additional, Kuder, Julia F., additional, Murphy, Sabina A., additional, Forni, Danielle M., additional, Kurtz, Christopher E., additional, Honarpour, Narimon, additional, Keech, Anthony C., additional, Sever, Peter S., additional, Pedersen, Terje R., additional, and Sabatine, Marc S., additional

Published
2020
Full Text
View/download PDF

37. Cognition After Lowering LDL-Cholesterol With Evolocumab

Author

Gencer, Baris, primary, Mach, François, additional, Guo, Jianping, additional, Im, KyungAh, additional, Ruzza, Andrea, additional, Wang, Huei, additional, Kurtz, Christopher E., additional, Pedersen, Terje Rolf, additional, Keech, Anthony C., additional, Ott, Brian R., additional, Sabatine, Marc S., additional, and Giugliano, Robert P., additional

Published
2020
Full Text
View/download PDF

38. THE EFFECT OF THE CARDIAC MYOSIN ACTIVATOR, MECAMTIV MECARBIL, ON RIGHT VENTRICULAR STRUCTURE AND FUNCTION IN CHRONIC SYSTOLIC HEART FAILURE (COSMIC-HF)

Author

Biering-Sorensen, Tor, primary, Papolos, Alexander, additional, Teerlink, John, additional, Felker, G. Michael, additional, McMurray, John, additional, Legg, Jason, additional, Malik, Fady, additional, Honarpour, Narimon, additional, Kurtz, Christopher, additional, and Solomon, Scott D., additional

Published
2020
Full Text
View/download PDF

39. BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE)

Author

Teerlink, John R., primary, Diaz, Rafael, additional, Felker, G. Michael, additional, McMurray, John, additional, Metra, Marco, additional, Solomon, Scott D., additional, Legg, Jason, additional, Varin, Claire, additional, Kurtz, Christopher, additional, Malik, Fady, additional, and Abbasi, Siddique A., additional

Published
2020
Full Text
View/download PDF

43. Buttons for Idiots - A Serious Game About the Daily Struggles of In-House User Experience Professionals

Author

Kurtz, Christopher, Käfer, Julia, and Hermenau, Thomas

Subjects
Adult Education, User Experience, Unity, Interaction, Communication, In-house UX, Serious Game, Knowledge Transfer, Software, 3D
Abstract

In this work we present our initial findings of leveraging a serious game for knowledge transfer between user experience professionals. “Buttons for Idiots” (BFI) is the prototype of a game designed to help user experience professionals to discover the influence of communication and other so-called soft skills on the effectiveness of their work. We will discuss the origins of the concept, give an outline of BFI’s development, and present the findings of its empirical evaluation during the “Mensch und Computer” 2020 conference. We conclude that serious games are a promising approach for knowledge transfer in the target demographic.

Published
2020
Full Text
View/download PDF

44. How to perform a comprehensive examination of the knee: the knee is a complex and easily injured joint. This step-by-step guide leads the physician assistant through a thorough examination to an accurate diagnosis

Author

Browne, Kerri and Kurtz, Christopher A.

Subjects
Physicians' assistants -- Practice -- Methods -- Usage, Physical diagnosis -- Methods -- Usage, Periodic health examinations -- Methods -- Usage, Knee -- Injuries, Health care industry
Abstract

The American Academy of Orthopaedic Surgeons reports that in 2003, 19.4 million Americans visited a physician because of a knee problem. (1) An increasing older population and a greater number [...]

Published
2009

46. Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure:The COSMIC-HF Trial

Author

Biering-Sorensen, Tor, Minamisawa, Masatoshi, Claggett, Brian, Liu, Jiankang, Felker, G. Michael, McMurray, John J. V., Malik, Fady I., Abbasi, Siddique, Kurtz, Christopher E., Teerlink, John R., Solomon, Scott D., Biering-Sorensen, Tor, Minamisawa, Masatoshi, Claggett, Brian, Liu, Jiankang, Felker, G. Michael, McMurray, John J. V., Malik, Fady I., Abbasi, Siddique, Kurtz, Christopher E., Teerlink, John R., and Solomon, Scott D.

Published
2020

47. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction:GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Author

Teerlink, John R., Diaz, Rafael, Felker, G. Michael, McMurray, John J. V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias-Mendoza, Alexandra, Biering-Sorensen, Tor, Bohm, Michael, Bonderman, Diana, Cleland, John G. F., Corbalan, Ramon, Crespo-Leiro, Maria G., Dahlstrom, Ulf, Echeverria Correa, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Candida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Lund, Mayanna, Macdonald, Peter, Mareev, Vyacheslav, Momomura, Shin-ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J. A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Abbasi, Siddique A., Varin, Claire, Malik, Fady I., Kurtz, Christopher E., Teerlink, John R., Diaz, Rafael, Felker, G. Michael, McMurray, John J. V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias-Mendoza, Alexandra, Biering-Sorensen, Tor, Bohm, Michael, Bonderman, Diana, Cleland, John G. F., Corbalan, Ramon, Crespo-Leiro, Maria G., Dahlstrom, Ulf, Echeverria Correa, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Candida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Lund, Mayanna, Macdonald, Peter, Mareev, Vyacheslav, Momomura, Shin-ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J. A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Abbasi, Siddique A., Varin, Claire, Malik, Fady I., and Kurtz, Christopher E.

Abstract

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fractionConclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.

Published
2020

48. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Author

Teerlink, John R., Díaz, Rafael, Felker, G. Michael, McMurray, John J.V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias‐Mendoza, Alexandra, Biering‐Sørensen, Tor, Böhm, Michael, Bonderman, Diana, Cleland, John G.F., Corbalán, Ramón, Crespo-Leiro, María Generosa, Dahlström, Ulf, Echeverría Correa, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Cándida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Li, J., Lund, Mayanna, Macdonald, Peter, Mareev, Vyacheslav, Momomura, Shin‐ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J.A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Varin, Claire, Honarpour, N., Abbasi, Siddique A., Malik, Fady I., Kurtz, Christopher E., Teerlink, John R., Díaz, Rafael, Felker, G. Michael, McMurray, John J.V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias‐Mendoza, Alexandra, Biering‐Sørensen, Tor, Böhm, Michael, Bonderman, Diana, Cleland, John G.F., Corbalán, Ramón, Crespo-Leiro, María Generosa, Dahlström, Ulf, Echeverría Correa, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Cándida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Li, J., Lund, Mayanna, Macdonald, Peter, Mareev, Vyacheslav, Momomura, Shin‐ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J.A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Varin, Claire, Honarpour, N., Abbasi, Siddique A., Malik, Fady I., and Kurtz, Christopher E.

Abstract

[Abstract] BACKGROUND. The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS. We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS. During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P=0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro–B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS. Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.)

Published
2020

49. Letter to the Editor

Author

Sekiya, Jon K., Kurtz, Christopher A., and Whiddon, David R.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results